The Conversation (0)
Love Pharma Inc. (CSE: LUV) (FSE: G1Q0) continues to prioritize the necessity for clinical validation as a vital step in bringing its products to market. The Vancouver, Canada-based company, which operates as a specialized health and wellness company that licenses and distributes psychedelic and cannabis-infused products, has established a practice of offering proven products with clinical data, user studies, and scientific research to support its claims. It's a practice that gives Love Pharma a distinct market advantage over many of its competitors. And now, Love Pharma is set to broaden that advantage with its recent announcement that the company has signed a Letter of Intent to acquire MicroDoz Therapy, Inc.
The benefit of this acquisition to Love Pharma, its shareholders and worldwide consumers is that the company gains MicroDoz's exclusive partnership with a world-renowned university to conduct a landmark study into the efficacy of psilocybin assisted treatment of cannabis use disorder. Love Pharma can leverage this relationship to further expand its product lineup, strengthen its clinical validation program, and add to its comprehensive portfolio of intellectual property.
Specifically, the acquisition will further substantiate the company's efforts to become a frontrunner in the psychedelics and therapeutics space. Love Pharma's Chief Executive Officer (CEO), Zach Stadnyk, said his company's existing portfolio, which consists of the exclusive rights to 7 novel therapeutic products focused on mental and sexual wellness, is already at the leading edge of innovation in the industry. So, continued new product development will further build upon what is already a strong foundation. Stadnyk's goal is to establish a growing and loyal customer base as the company seeks to define the psychedelics and therapeutics industry with solid science that leads to effective products.
When explaining the acquisition of MicroDoz Therapy, the CEO stated, "Science and efficacy are paramount to our strategy, as a result we seized the opportunity to acquire MicroDoz to expedite what will be a landmark study with a world-leading university."
As an entry point into the burgeoning psychedelics market, the company acquired the rights to the patent-pending psilocybin strip in addition to the acquisition of MicroDoz, which has the exclusive partnership to the landmark study at an unnamed leading global university. Love Pharma announced it expects to release the university's name along with details of the program when the definitive agreement is closed.
Psilocybin is the psychoactive chemical in "magic mushrooms," and the company's biosynthetic psilocybin-infused oral strip utilizes the already-proven and existing novel technology implemented for the company's mucoadhesive CBD strip product, "Auralief." Auralief, the company's discreet cannabis-infused oral strip that speeds-up and enhances the desired effects of THC and CBD, is supported by a recent human trial that demonstrated a greater than 30% increase in efficacy and speed to performance of THC and CBD.
Following the U.S. Food and Drug Administration's (FDA) "breakthrough" designation in 2018, psilocybin gained legitimacy in the mental health field. The breakthrough designation has prompted the FDA to fast-track drug trials using psilocybin, and it has become the empetus behind an emerging health and wellness market. Love Pharma has stated that ensuring the safety of users through reliable systems of accurate dosing remains of paramount importance. Achieving accurate dosing is difficult with botanicals; however, pioneering companies, including Love Pharma, are developing new extracted products designed to deliver the most consistently accurate dosing possible.
In late October, Love Pharma announced that it's currently developing a mucoadhesive sublingual strip. The Company is partnering with the strip's creator, a US-based pharmaceutical company, to develop the strip for use as a psilocybin delivery system.
And as prominent medical institutions and research facilities in the United Kingdom and the U.S. continue to conduct clinical studies and trials to determine the efficacy of psilocybin in treating a host of debilitating conditions, Love Pharma's acquisition should thrust the company into a leading role as it expedites what will be a landmark study into the efficacy of psilocybin assisted treatment of cannabis use disorder.
To learn more about Love Pharma Inc., visit https://love-pharma.com or email investors@love-pharma.com
About Love Pharma Inc.
Love Pharma Inc. is a new-age pharma/nutraceutical company specializing in the global sexual health, wellness, and psychedelics markets. Founded in 2020, Love Pharma's mission is to bring innovative products to market that enhance sexual health and wellness while providing an improved quality of life. Love Pharma holds exclusive licenses to produce, market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.
About Stock Market Media Group
Stock Market Media Group is a news and media content development IR firm offering a platform for corporate stories to unfold in the media with press releases, feature news articles, research reports, corporate videos, and radio-style CEO interviews.
This article was written based on publicly available information. Stock Market Media Group may, from time to time, include our own opinions about the companies, their business, markets and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at www.sec.gov. We also recommend, as a general rule, that before investing in any securities, you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks. We are not a registered broker, dealer, analyst, or advisor. We hold no investment licenses and may not sell, offer to sell, or offer to buy any security. Our publications about Love Pharma are not a recommendation to buy or sell a security.
Should Stock Market Media Group and its management own shares in the profiled company, they may benefit from any increase in the share price of the profiled companies and hold the right to sell the shares bought at any given time including shortly after the release of the company's profile. Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment. Under the Securities Act of 1933, Section 17(b), Stock Market Media Group discloses that it was remunerated one-thousand, two hundred dollars paid for by a third party via bank wire, to produce this content related to Love Pharma.
Stock Market Media Group and its management do not own any shares in Love Pharma and never accepts compensation in free-trading shares for its marketing services of the company being profiled, however third parties that have compensated Stock Market Media Group may hold free-trading shares of the company being profiled and could very well be selling, holding or buying shares of the company's stock at the same time the content is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.
If Stock Market Media Group ever accepts compensation in the form of free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the company's profile, our disclaimer will be updated accordingly to reflect the current position of any free trading shares received as compensation for our services.
For more information: www.stockmarketmediagroup.com
Stock Market Media Group info@stockmarketmediagroup.com
View original content to download multimedia: 
